GALT - ガレクチン・セラピュ―ティクス (Galectin Therapeutics Inc.) ガレクチン・セラピュ―ティクス

 GALTのチャート


 GALTの企業情報

symbol GALT
会社名 Galectin Therapeutics Inc (ガレクチン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ガレクチン・セラピューティクス(Galectin Therapeutics Inc.)(旧名:プロ・ファーマシューティカル(Pro-Pharmaceuticals Inc.))は開発段階の会社。同社はガレクチン(Galectin)を標的とする治療薬の発見・開発に従事する。同社は多糖ポリマーを用いた抗癌治療法の開発に集中する。平成21年12月31日現在、同社の製品は前臨床および臨床試験を含み、開発中にある。平成21年12月31日現在、同社は、「Avastin」など生物製剤と「5-FU」など化学療法と併用できる一連の化合物を開発している。平成21年12月31日現在、「DAVANAT」は第I相および第II相試験で約100人のがん患者に投与されている。平成21年12月31日現在、同社は肝臓と腎臓の線維症など他の重篤な疾患を治療する他の治療用化合物を開発している。これらの製品候補は、すべてが開発の前臨床段階にある。   ガレクチン・セラピュ―ティクスは、米国の医薬品研究開発会社。肝線維性疾患とがんの治療法を開発する。同社の薬剤候補は、生物学的および病理学的機能の主要な役割を持つガレクチン・タンパク質を標的とする方法に基づいている。開発中の薬剤「GR-MD-02」は、免疫システム調節剤を複数組み合わせ、肝線維症やがん治療に使用される。本社はジョ―ジア州。   
本社所在地 4960 Peachtree Industrial Blvd. Suite 240 Norcross GA 30071 USA
代表者氏名 Richard E. Uihlein リチャード・E・ウイ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 678-620-3186
設立年月日 36708
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 7人
url www.galectintherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/galt
adr_tso
EBITDA EBITDA(百万ドル) -14.72400
終値(lastsale) 5.16
時価総額(marketcap) 211115491.8
時価総額 時価総額(百万ドル) 202.11440
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 200.56940
当期純利益 当期純利益(百万ドル) -16.10000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 14% to $8.7M. Lower net loss reflects Research and development decrease of 62% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.29 to -$0.23.

 GALTのテクニカル分析


 GALTのニュース

   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin  2021/04/19 12:00:00 Yahoo Finance
Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. UihleinNORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has engaged Dr. Ben Carson, Sr., a world-renowned neurosurgeon and the 17th Secretary of the U.S. Department of Housing and Urban Development, as a special consultant to assist with development of the Company’s galectin-3 inhibitor, belapectin, as a treatment for NASH cirrhosis and in combination with immunotherapy for the treatment of cancers. The Company engaged Dr. Carson to increase awareness of Galectin Therapeutics including its ongoing Phase 2b/3 NAVIGATE clinical trial in NASH cirrhosis, its continuing research in combination with cancer immunotherapy, and its potential in addressing other fibrotic diseases. Dr. Carson will also assist in the formation of a scientific advisory committee for the Company, recruit potential members of the committee, and identify potential strategic commercial and/or academic partners for the Company.
   What's Going On With GALT Stock And TV Stock Today?  2021/04/14 15:12:46 Benzinga
Galectin Therapeutics Inc (NASDAQ: GALT ) shares are trading higher after the company … Full story available on Benzinga.com
   Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response  2021/04/14 12:28:27 Benzinga
Galectin Therapeutics Inc (NASDAQ: GALT ) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and melanoma. The study assessing belapectin combined with Merck's & Co's (NYSE: MRK ) … Full story available on Benzinga.com
   Galectin Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/03/15 22:31:00 Stock Market Daily
Galectin Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin  2021/04/19 12:00:00 Yahoo Finance
Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. UihleinNORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has engaged Dr. Ben Carson, Sr., a world-renowned neurosurgeon and the 17th Secretary of the U.S. Department of Housing and Urban Development, as a special consultant to assist with development of the Company’s galectin-3 inhibitor, belapectin, as a treatment for NASH cirrhosis and in combination with immunotherapy for the treatment of cancers. The Company engaged Dr. Carson to increase awareness of Galectin Therapeutics including its ongoing Phase 2b/3 NAVIGATE clinical trial in NASH cirrhosis, its continuing research in combination with cancer immunotherapy, and its potential in addressing other fibrotic diseases. Dr. Carson will also assist in the formation of a scientific advisory committee for the Company, recruit potential members of the committee, and identify potential strategic commercial and/or academic partners for the Company.
   What's Going On With GALT Stock And TV Stock Today?  2021/04/14 15:12:46 Benzinga
Galectin Therapeutics Inc (NASDAQ: GALT ) shares are trading higher after the company … Full story available on Benzinga.com
   Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response  2021/04/14 12:28:27 Benzinga
Galectin Therapeutics Inc (NASDAQ: GALT ) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and melanoma. The study assessing belapectin combined with Merck's & Co's (NYSE: MRK ) … Full story available on Benzinga.com
   Galectin Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/03/15 22:31:00 Stock Market Daily
Galectin Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin  2021/04/19 12:00:00 Yahoo Finance
Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. UihleinNORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has engaged Dr. Ben Carson, Sr., a world-renowned neurosurgeon and the 17th Secretary of the U.S. Department of Housing and Urban Development, as a special consultant to assist with development of the Company’s galectin-3 inhibitor, belapectin, as a treatment for NASH cirrhosis and in combination with immunotherapy for the treatment of cancers. The Company engaged Dr. Carson to increase awareness of Galectin Therapeutics including its ongoing Phase 2b/3 NAVIGATE clinical trial in NASH cirrhosis, its continuing research in combination with cancer immunotherapy, and its potential in addressing other fibrotic diseases. Dr. Carson will also assist in the formation of a scientific advisory committee for the Company, recruit potential members of the committee, and identify potential strategic commercial and/or academic partners for the Company.
   What's Going On With GALT Stock And TV Stock Today?  2021/04/14 15:12:46 Benzinga
Galectin Therapeutics Inc (NASDAQ: GALT ) shares are trading higher after the company … Full story available on Benzinga.com
   Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response  2021/04/14 12:28:27 Benzinga
Galectin Therapeutics Inc (NASDAQ: GALT ) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and melanoma. The study assessing belapectin combined with Merck's & Co's (NYSE: MRK ) … Full story available on Benzinga.com
   Galectin Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/03/15 22:31:00 Stock Market Daily
Galectin Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Insider Sells Galectin Therapeutics Stock  2021/01/19 11:15:00 Benzinga
A Form 4 filing filed with the SEC on Tuesday, January 19 showed that Amelio Gilbert F sold 60,000 shares of Galectin Therapeutics Inc …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ガレクチン・セラピュ―ティクス GALT Galectin Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)